



NEW ANALYSIS: Return on Investment in Research Commercialisation

New analysis by Science & Technology Australia shows the new research commercialisation fund would generate \$17.6 billion in returns to Australia's economy by using the playbook of our nation's brightest commercialisation stars.

The Australian Government last month announced a new \$2.2 billion investment in university research commercialisation.

\$1.6 billion will go into a new research commercialisation fund to deliver kickstarter capital for innovators to develop their technologies to the stage where they can secure private sector venture capital.

The new modelling calculated the rates of investment and returns for an Australian research centre that has focussed on commercialisation from the very start of its research program.

The research centre's success has been achieved by adopting a 'bench-to-boardroom' mindset to equip its scientists and researchers to create new startup companies.

The Australian Research Council Centre of Excellence in Nanoscale BioPhotonics (CNBP) leveraged an initial investment of \$23 million and worked with commercialisation and market experts from the start.

Over the past seven years, the centre has created 16 startups with a combined market capitalisation and market impact value of \$519.1 million.

This is a 22-fold return to Australia's economy on the initial investment.

The new analysis by Science & Technology Australia assesses the likely returns if the new research commercialisation fund announced last month took a similar approach.

It estimates conservatively that even if only half the outlay in the new fund - \$800 million - delivered a similar rate of return, **it would generate a \$17.6 billion return on investment to Australia's economy.**

This is the scale of the windfall gain to Australia that is possible from investing in research commercialisation and a bench-to-boardroom initiative.

The analysis shows that once just five per cent - a very conservative figure - of the innovators backed by the new scheme are successful on the scale the CNBP team has been - then the new fund will already have paid for itself.

Everything above that five per cent success rate would be a windfall gain to Australia.


The new fund's role will be to spur more promising Australian science and research across the current 'valley of death' in commercialisation.

Science & Technology Australia President Professor Mark Hutchinson is a scientist-entrepreneur and Director of the CNBP. Australia needs to train more bench-to-boardroom scientists like those at his centre to truly capitalise on its investment in research commercialisation.

The 16 new companies and startups generated by his centre include Miniprobos (estimated by Meat and Livestock Australia to add \$183 million of value each year to the red meat industry),

MEQ Probe, Life Whisperer, Fertilis, ART Lab Solutions, Dairy Ex, Woven Optics, Spectral Change, Lucigem, Science Bees, Ezy Glas Technology, Quantitative, IVOS Sensor, 3D Cell, High Temp Sensor, and Radiodynamic Therapeutics.

Together, these companies have created 70 new jobs across Australia - and counting.



BY THE NUMBERS

THE AUSTRALIAN RESEARCH COUNCIL CENTRE OF EXCELLENCE IN NANOSCALE BIOPHOTONICS

\$23 million investment

RETURNS

\$519.1 million

A 22-fold return on investment

16 new startups

70 new jobs across Australia

NEW AUSTRALIAN RESEARCH COMMERCIALISATION FUND

With success on the scale of CNBP:

A 22-fold return on investment

WOULD TURN AN

\$800
million

INVESTMENT

INTO RETURNS OF

\$17.9
billion